<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03439397</url>
  </required_header>
  <id_info>
    <org_study_id>GZWACMC20180112</org_study_id>
    <nct_id>NCT03439397</nct_id>
  </id_info>
  <brief_title>RCT of Ballon Technique VS Selective Ophthalmic Artery Infusion For the Retinoblastoma Patients</brief_title>
  <official_title>RCT of Ballon Technique VS Selective Ophthalmic Artery Infusion For the Retinoblastoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou Women and Children's Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou Women and Children's Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retinoblastoma is the most common intraocular tumor in children..IAC--Targeted Treatment for
      Intraocular Retinoblastoma,Is minimally invasive procedure that infuse chemotherapy select
      into the ophthalmic artery, its can increasing the drug concentration reaching the tumor and
      reducing systemic toxicity compared with traditional intravenous treatment.: one is Ballon
      technique , another is selective ophthalmic artery infusion.This study evaluates the
      difference of Ballon technique and selective ophthalmic artery infusion effect in the
      treatment of retinoblastoma. Half of participants will receive, Ballon technique while the
      other half will receive selective ophthalmic artery infusion
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Delivering the chemotherapeutic agent in the arterial system through the ophthalmic artery
      transforms the treatment of retinoblastoma from systemic chemotherapy to local chemotherapy.
      Two alternative means can be used,The purpose of this study is to show that Ballon technique
      and SOAI delivered directly through the artery supplying the eye (ophthalmic artery) to
      patients with retinoblastoma is a safe and effective treatment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Globe salvage rate (Eyes saved/Eyes treated)</measure>
    <time_frame>Three years from intervention</time_frame>
    <description>Event defined as the need for external beam enucleation，To assess the saving of eyes affected with IAC for patients who would have been candidates for enucleation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual pathway function</measure>
    <time_frame>Three years from intervention</time_frame>
    <description>Evaluation of visual pathway function will be measured composite using visual acuity, electroretinogram, visual evoked potential, and functional magnetic resonance imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complications</measure>
    <time_frame>Three years from intervention</time_frame>
    <description>Short and long term complications</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">496</enrollment>
  <condition>Retinoblastoma</condition>
  <condition>IAC</condition>
  <condition>Selective Ophthalmic Artery Infusion</condition>
  <condition>Ballon Technique</condition>
  <arm_group>
    <arm_group_label>Ballon Technique group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention：Ballon Technique</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOAI group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention：Selective Ophthalmic Artery Infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ballon Technique</intervention_name>
    <description>Ballon Technique</description>
    <arm_group_label>Ballon Technique group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SOAI</intervention_name>
    <description>SOAI</description>
    <arm_group_label>SOAI group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. No age limit, no gender limit, monocular or binocular affected;

          2. New diagnosed cases, without any previous treatment;

          3. Clinical diagnosed as retinoblastoma, and in group C, D or E according to IIRC
             standard; Binocular affected with one eye enucleated;

          4. Normal bone marrow function

          5. Normal liver function

          6. Normal kidney function

          7. Normal coagulation function

          8. To be willing to take part in the clinical trial and sign the informed consent form;
             9. To be willing to have these tumor sites surgically removed and do the follow up
             accordingly.

        Exclusion Criteria:

          1. Diagnosis is not clear;

          2. With other sever ocular diseases (for example: neovascular glaucoma, iris
             neovascularization);

          3. With sever systemic diseases, include abnormal liver or kidney function, abnormal
             routine blood test or coagulation function, congenital heart diseases and dysaudia;

          4. Took part in other clinical study within 3 months;

          5. Refuse to take part in this clinical study;

          6. Is not willing to do the follow up accordingly or follow up less than 2 times.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>huiming xia</last_name>
    <role>Study Director</role>
    <affiliation>Guangzhou Women and Children's Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>jing zhang</last_name>
    <phone>136262828465</phone>
    <email>fejr@foxmail.com</email>
  </overall_contact>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2018</study_first_submitted>
  <study_first_submitted_qc>February 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2018</study_first_posted>
  <last_update_submitted>February 28, 2018</last_update_submitted>
  <last_update_submitted_qc>February 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou Women and Children's Medical Center</investigator_affiliation>
    <investigator_full_name>Jing zhang</investigator_full_name>
    <investigator_title>Jing Zhang, Head of Department of Interventional Radiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinoblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

